Choi JY, et al. - Given that a previous study has reported an increased level of chitinase 3 like 1 (CHI3L1) in plasma in Alzheimer’s disease (AD) patients, researchers assessed the inhibitory impact of 2-({3-[2-(1-cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2-quinazolinyl}sulfanyl)-N-(4-ethylphenyl)butanamide (K284-6111), an inhibitor of CHI3L1, on memory impairment in amyloid beta (Aβ)_1–42-infused mice, and microglial BV-2 cells and astrocytes. They observed reduction of Aβ_1–42-induced expression of inflammatory proteins (inducible nitric oxide synthase, cyclooxygenase 2, glial fibrillary acidic protein, and ionized calcium-binding adapter molecule 1) and the suppression of CHI3L1 expression in the brain in relation to a memory recovery effect. Overall, findings indicate the possible utility of CHI3L1 inhibitor as an applicable intervention drug in amyloidogenesis and neuroinflammation, thereby preventing memory dysfunction via inhibition of nuclear transcription factor-kappa B.